Abbott Vascular

What Abbott Vascular does

Abbott Cardiovascular — operating under the public-facing brand Abbott Vascular — is the cardiovascular medical devices division of Abbott Laboratories (NYSE: ABT), a 1888-founded, Fortune 500 healthcare company headquartered in Illinois. The division designs, manufactures, and commercializes Class III implantable and interventional devices across five therapeutic areas: Cardiac Rhythm Management (pacemakers, ICDs, CRT-Ds, leadless pacemakers, implantable cardiac monitors), Electrophysiology (EnSite Precision and EnSite X cardiac mapping systems, ablation catheters), Heart Failure (CardioMEMS HF remote pulmonary artery pressure monitor, HeartMate II and HeartMate 3 LVADs, CentriMag acute blood pump), Structural Heart (MitraClip transcatheter mitral valve repair, Amplatzer occluder family including the TorqVue LP delivery system), and Vascular Intervention (OPTIS OCT imaging systems, PressureWire X FFR guidewire, QUANTIEN and Ultiri measurement systems, and the Esprit BTK drug-eluting resorbable scaffold). The technology stack combines proprietary materials science (notably Optim lead insulation, demonstrated at 50x the abrasion resistance of silicone) with a software-and-services layer (Merlin PCS programmer, Merlin@home transmitter, myMerlin mobile app, Merlin.net remote monitoring cloud, HeartMate Touch Communication System) that creates continuous touchpoints with implanted patients.

The division's commercial model is primarily direct-to-hospital field sales of capital equipment and high-value disposables into electrophysiology labs, cardiac catheterization labs, and cardiac surgery programs across the Americas, EMEA, and APAC. Revenue is generated through hardware sales of implants and capital systems, complemented by recurring procedural pull-through (leads, ablation catheters, imaging catheters, scaffolds) and by post-implant service revenue tied to programmer software, remote monitoring subscriptions, and patient management services. Customers are enterprise healthcare providers — electrophysiologists, interventional cardiologists, heart failure specialists, and cardiac surgeons — while a secondary patient/caregiver segment receives device education, travel support, and remote monitoring services. Pricing is not publicly disclosed and is negotiated through multi-year contracts with hospitals, group purchasing organizations, and government payers, with Abbott providing dedicated reimbursement and coding resources by country. The product portfolio includes legacy brands inherited from the 2016 St. Jude Medical acquisition (Assurity, Accent, Anthem, Gallant, Fortify, Quadra Assura, Unify) alongside next-generation platforms (AVEIR leadless pacemakers, Esprit BTK, Gallant with Bluetooth, EnSite X). The division maintains the largest post-market surveillance program in implantable cardiac device history — over 10,000 patients, 292 sites, 571 physicians, and 24,000+ patient-years of follow-up — and publishes semi-annual Product Performance Reports that double as a clinical credibility asset.

Name

Abbott Vascular

Legal name

Abbott

Website

https://cardiovascular.abbott

Company type

Public

Founded year

1888

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Abbott Cardiovascular develops and sells Class III implantable and interventional medical devices — pacemakers, ICDs, leadless pacemakers, mapping and ablation systems, LVADs, structural heart occluders, OCT/FFR imaging, and drug-eluting scaffolds — to hospitals, electrophysiologists, interventional cardiologists, and heart failure specialists across the Americas, EMEA, and APAC.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

akta.pro secondary industries

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG), Electrophysiology Mapping & Ablation Systems (HLAHAFAD), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

Keywords

• Cardiovascular medical devices
• Cardiac rhythm management
• Electrophysiology systems
• Structural heart devices
• Vascular intervention products

Headquarters

HQ city

Lucerne Valley

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Implantable Cardiac Devices: Abbott generates revenue through the sale of implantable cardiac rhythm management devices including pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy devices (CRT-P/CRT-D), implantable cardiac monitors (ICMs), and leadless pacemakers. These devices are sold to hospitals and electrophysiology labs for implantation in patients with cardiac arrhythmias and heart failure.
2. Electrophysiology Products: Revenue from electrophysiology mapping systems, ablation catheters, and related capital equipment used in cardiac ablation procedures for atrial fibrillation treatment. Includes the EnSite Precision and EnSite X EP cardiac mapping systems.
3. Heart Failure Products: Sales of CardioMEMS HF System for pulmonary artery pressure monitoring and HeartMate ventricular assist devices for advanced heart failure treatment. These products serve patients with chronic and advanced heart failure requiring hemodynamic monitoring or mechanical circulatory support.
4. Vascular Intervention Products: Revenue from coronary and peripheral vascular intervention products including OCT imaging systems (OPTIS), fractional flow reserve guidewires (PressureWire), drug-eluting stents, balloon catheters, and the Esprit BTK drug-eluting resorbable scaffold for below-the-knee peripheral artery disease.
5. Structural Heart Products: Sales of structural heart devices including MitraClip for mitral valve repair and Amplatzer occluder devices for septal defect closure. These products are used in minimally invasive cardiac procedures.
6. Product Donations (Charitable Program): Abbott operates a Medical Device Grants Program that includes product donations for indigent patients and international humanitarian missions. While donations are provided at no cost, they support brand loyalty and market access in underserved regions.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Abbott Vascular, through its Cardiovascular division, manufactures and sells a comprehensive portfolio of cardiovascular medical devices across five therapeutic areas: Cardiac Rhythm Management (pacemakers, ICDs, CRT-Ds, leadless pacemakers, implantable cardiac monitors), Electrophysiology (3D cardiac mapping systems and ablation products), Structural Heart (MitraClip transcatheter mitral valve repair, Amplatzer occluders), Heart Failure (CardioMEMS remote pulmonary artery pressure monitor, HeartMate left ventricular assist systems, CentriMag blood pumps), and Vascular Intervention (OPTIS OCT imaging, PressureWire FFR guidewires, Esprit BTK drug-eluting resorbable scaffold). Devices are implanted in patients or used in interventional procedures by electrophysiologists, interventional cardiologists, heart failure specialists, and cardiac surgeons.

Product overview

Abbott Vascular, through its Cardiovascular division, offers a comprehensive portfolio of medical devices organized into five core therapeutic areas: Cardiac Rhythm Management (pacemakers, ICDs, leads, leadless pacemakers), Electrophysiology (EnSite mapping systems, ablation products), Structural Heart (MitraClip, Amplatzer occluders), Heart Failure (CardioMEMS HF System, HeartMate LVAS, CentriMag), and Vascular (OPTIS OCT systems, PressureWire FFR, QUANTIEN measurement). The portfolio includes multiple product families acquired from St. Jude Medical, including pacemakers (Assurity, Accent, Endurity, Zenus), ICDs/CRT-Ds (Gallant, Fortify, Quadra Assura, Unify), and monitoring systems (Merlin.net, Merlin@home). Abbott's ecosystem integrates implantable devices with remote monitoring platforms (Merlin.net, myMerlin app) and programmer systems (Merlin PCS) to enable comprehensive patient management across cardiovascular conditions.

Differentiator

Problem solved

Functional benefit

Brands

• HeartMate: Left ventricular assist devices (LVADs) for patients with advanced heart failure
• MitraClip
• CardioMEMS
• Confirm Rx
• AVEIR
• EnSite Precision
• Amplatzer
• OPTIS Systems

Products and services

• Cardiac Rhythm Management Devices Implantable devices including pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy devices (CRT-P and CRT-D), implantable cardiac monitors (ICMs), and implantable leads for treating cardiac rhythm disorders in patients with arrhythmias and heart failure. Implanted by electrophysiologists in hospitals and EP labs.
• AVEIR Leadless Pacemaker System Leadless pacemaker system including AVEIR VR (single-chamber) and AVEIR DR (dual-chamber) for patients requiring cardiac pacing without transvenous leads. Implanted directly in the heart via catheter by electrophysiologists.
• Confirm Rx Insertable Cardiac Monitor Insertable cardiac monitor with wireless connectivity for smartphone-based patient monitoring, used for long-term arrhythmia detection in patients with suspected rhythm abnormalities.
• Assert-IQ Insertable Cardiac Monitor Implantable cardiac monitor with enhanced sensing capabilities for long-term rhythm monitoring and detection of infrequent arrhythmias.
• EnSite Precision Cardiac Mapping System Three-dimensional electrophysiology mapping and visualization system used during cardiac ablation procedures for diagnosing and treating arrhythmias such as atrial fibrillation, with enhanced accuracy and EU RED 2014/53/EU compliance.
• EnSite X EP System Advanced next-generation electrophysiology mapping system providing real-time cardiac visualization for ablation procedures.
• MitraClip Delivery System Transcatheter mitral valve repair system for treatment of mitral regurgitation without open-heart surgery, used by interventional cardiologists and cardiac surgeons in structural heart procedures.
• Amplatzer TorqVue LP Delivery System Steerable delivery catheter system used for implanting Amplatzer occluder devices during structural heart procedures such as septal defect closure and left atrial appendage occlusion.
• CardioMEMS HF System Remote hemodynamic monitoring system comprising a Hospital System, Patient Electronics System, and implantable pulmonary artery (PA) pressure sensor for managing chronic heart failure patients. Provides daily pulmonary artery pressure readings to clinicians for proactive heart failure management.
• HeartMate 3 Left Ventricular Assist System (LVAS) Mechanical circulatory support device (LVAD) for patients with advanced heart failure, providing long-term ventricular support as a bridge to transplant or destination therapy. Pairs with HeartMate Touch Communication System for monitoring.
• HeartMate II LVAS Mechanical circulatory support system for end-stage heart failure patients awaiting transplantation or recovery, providing intermediate-to-long-term left ventricular support.
• CentriMag Blood Pump Acute circulatory support system providing temporary mechanical circulatory support during cardiac procedures or in post-cardiotomy shock scenarios.
• OPTIS Imaging Systems Optical Coherence Tomography (OCT) imaging systems including OPTIS Integrated System, OPTIS Mobile System, and OPTIS Mobile Next Imaging System used for intravascular imaging during PCI procedures to guide coronary intervention.
• PressureWire X Guidewire Pressure-measurement guidewire for Fractional Flow Reserve (FFR) assessment of coronary artery blockages during diagnostic and interventional coronary procedures. Manufactured at Abbott's Plainsview and Westford facilities.
• QUANTIEN Measurement System Quantitative coronary angiography measurement system for precise assessment of coronary lesions during interventional procedures.
• Ultiri Measurement System Intravascular imaging measurement system for coronary intervention planning and assessment.
• Esprit BTK Drug-Eluting Resorbable Scaffold Drug-eluting resorbable scaffold (DRS) for below-the-knee peripheral artery disease treatment in patients with chronic limb-threatening ischemia. LIFE-BTK trial demonstrated 61.5% primary efficacy vs 32.8% for PTA at 2 years.
• Merlin.net Patient Care Network Remote monitoring platform enabling clinicians to monitor patient device data remotely for pacemakers, ICDs, CRT-Ds, and ICMs. Includes battery performance alerts and cybersecurity firmware upgrades for connected implantable devices.
• Merlin@home Transmitter Remote monitoring transmitter for automatic transmission of patient implantable cardiac device data from home to the Merlin.net Patient Care Network.
• Merlin 3650 Patient Care System Programmer system used by clinicians to interrogate and program Abbott implantable cardiac devices during in-clinic visits.
• myMerlin Mobile Application Mobile application enabling patients to monitor their Abbott implantable cardiac device and share data with healthcare providers.
• HeartMate Touch Communication System Communication system enabling HeartMate LVAS patients and clinicians to monitor and manage ventricular assist device performance.

Quantifiable outcome

• 98% reduction in externalized conductors for Durata leads vs Riata leads (CLAS study)
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Boston Scientific: Boston Scientific's Cardiology division competes directly in CRM (Accolade pacemakers, Resonate ICDs), EP (FARAWAVE pulsed-field ablation, Rhythmia mapping), structural heart (WATCHMAN FLX, ACURATE neo), and peripheral vascular (Eluvia DES, Ranger DCB). Major multi-therapy competitor.
• Shockwave Medical (J&J): Shockwave's intravascular lithotripsy (IVL) for calcified peripheral and coronary artery disease competes with Abbott's vascular intervention portfolio including Esprit BTK and OPTIS imaging. Acquired by J&J in 2024.
• Johnson & Johnson (Biosense Webster / Cerenovus): J&J's Biosense Webster division competes in electrophysiology with CARTO 3 mapping and the Pentacath/THERMOCOOL ablation portfolio, directly challenging EnSite Precision. J&J also entered vascular intervention via the Shockwave Medical acquisition.
• Medtronic: Medtronic's Cardiac and Vascular Group directly competes across all five of Abbott Cardiovascular's therapy areas, including Micra leadless pacemakers vs AVEIR, Arctic Front cryoablation vs EnSite, and CoreValve/Evolut TAVR vs structural heart. Most direct comprehensive competitor.
• Edwards Lifesciences: Edwards competes most directly in structural heart with the SAPIEN TAVR platform and the PASCAL mitral repair system, which competes with Abbott's MitraClip. Also expanding into heart failure and critical care monitoring.
• Philips (Image-Guided Therapy): Philips competes in interventional cardiology and vascular imaging via its Azurion and iFR/FFR physiology offerings, IntelliSpace Portal, and laser atherectomy (Phoenix), with significant overlap in cath lab capital equipment and diagnostic catheters.

Broad incumbents

• GE HealthCare: GE HealthCare provides cardiology imaging systems, ECG/monitoring platforms, and peri-procedural tools that compete with and complement Abbott's cardiac diagnostic and vascular imaging offerings across the cardiovascular care pathway.

Regional players

• Penumbra: Penumbra focuses on mechanical thrombectomy for peripheral vascular and neurovascular applications, with the Indigo and Lightning product lines; overlaps with Abbott's peripheral intervention portfolio in the vascular surgery setting.

Emerging players

• InspireMD: InspireMD develops the CGuard carotid embolic prevention stent system and is developing drug-eluting stents for peripheral artery disease, overlapping with Abbott's vascular intervention franchise in the underpenetrated PAD/PAD-BTK space.
• AtriCure: AtriCure is a focused EP player specializing in surgical and hybrid atrial fibrillation ablation (Isolator Synergy clamp, cryoICE probe), complementing rather than fully overlapping with Abbott's catheter-based EP franchise; competes in the converging surgical/catheter ablation space.

Market position

Strengths5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

• Xx.com/abbottglobal
• Facebookfacebook.com/info

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbott Vascular